Woods H F, Weston M J, Bunting S, Moncada S, Vane J
Artif Organs. 1980 Aug;4(3):176-9. doi: 10.1111/j.1525-1594.1980.tb03930.x.
To evaluate the effects of prostacyclin (PGI2) on the bioincompatibility of charcoal hemoperfusion (CHP), platelet counts, platelet aggregate formation as measured by screen filtration pressure (SFP), plasma fibrinogen levels, and heparin activity monitored by calcium-thrombin clotting times (Ca-TCT) were compared during CHP in healthy dogs with heparin alone or heparin plus PGI2. Platelet losses (25 +/- 6 vs 83 +/- 2%: mean +/- SEM), rise in SFP (65 +/- 6 vs 249 +/- 25 mmHg), and fibrinogen consumption (20 +/- 5 vs 46 +/- 6%) were significantly less during CHP with PGI2 than with heparin only. In addition, rapid neutralization of heparin, as monitored by Ca-TCT, during CHP was prevented by PGI2. The use of PGI2 may allow a proper evaluation of the efficacy of CHP in conditions such as fulminant hepatic failure where, hitherto, incompatibility between blood and charcoal may have had deleterious effects.
为评估前列环素（PGI2）对活性炭血液灌流（CHP）生物不相容性的影响，在健康犬只进行CHP时，比较单独使用肝素或肝素加PGI2情况下的血小板计数、通过筛滤压（SFP）测量的血小板聚集形成、血浆纤维蛋白原水平以及通过钙 - 凝血酶凝血时间（Ca - TCT）监测的肝素活性。与仅使用肝素相比，使用PGI2进行CHP期间，血小板损失（25±6对83±2%：平均值±标准误）、SFP升高（65±6对249±25 mmHg）和纤维蛋白原消耗（20±5对46±6%）显著减少。此外，PGI2可防止CHP期间通过Ca - TCT监测到的肝素快速中和。在暴发性肝衰竭等情况下，血液与活性炭之间的不相容性可能产生有害影响，而使用PGI2可能有助于正确评估CHP的疗效。
